Denali Therapeutics Inc. (NASDAQ:DNLI) Stock Has Average Target Price of $35.85 According to Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Denali Therapeutics, with 13 buys, two holds and one sell among 16 analysts. The average 12-month price target is $35.85, above the cited share price of $20.39.
• Institutional ownership is substantial at 92.92%. BlackRock initiated a roughly $360.8 million position, while Temasek, Dimensional Fund Advisors and Pictet Asset Management increased their stakes.
• Denali reported a quarterly loss of $0.68 per share, missing the consensus estimate of a $0.51 loss, although revenue of $3.60 million exceeded estimates of $2.15 million. An insider separately sold 2,768 shares under a pre-arranged trading plan.

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the sixteen analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and thirteen have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $35.85.

Several research firms have commented on DNLI. Sanford C. Bernstein reissued a "hold" rating on shares of Denali Therapeutics in a research report on Monday, June 22nd. JPMorgan Chase & Co. assumed coverage on Denali Therapeutics in a report on Monday, July 13th. They issued an "overweight" rating and a $29.00 target price for the company. UBS Group increased their price target on Denali Therapeutics from $25.00 to $34.00 and gave the company a "buy" rating in a research report on Friday, August 7th. Morgan Stanley lifted their price target on Denali Therapeutics from $35.00 to $36.00 and gave the stock an "overweight" rating in a report on Thursday, July 23rd. Finally, Wedbush reissued an "outperform" rating and issued a $26.00 price objective on shares of Denali Therapeutics in a research report on Monday, July 13th.

Insider Activity at Denali Therapeutics

In other news, insider Alexander O. Schuth sold 2,768 shares of Denali Therapeutics stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $23.44, for a total transaction of $64,881.92. Following the sale, the insider directly owned 278,995 shares in the company, valued at $6,539,642.80. The trade was a 0.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.70% of the stock is owned by insiders.

Institutional Trading of Denali Therapeutics

A number of large investors have recently added to or reduced their stakes in DNLI. BlackRock Inc. purchased a new position in Denali Therapeutics in the second quarter valued at about $360,759,000. Temasek Holdings Private Ltd increased its stake in shares of Denali Therapeutics by 30.9% during the 4th quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company's stock worth $115,784,000 after purchasing an additional 1,657,142 shares during the last quarter. Norges Bank purchased a new stake in shares of Denali Therapeutics during the 4th quarter worth approximately $84,525,000. Dimensional Fund Advisors LP raised its holdings in shares of Denali Therapeutics by 13.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,692,175 shares of the company's stock worth $51,687,000 after purchasing an additional 317,872 shares during the period. Finally, Pictet Asset Management Holding SA raised its holdings in shares of Denali Therapeutics by 92.5% in the 1st quarter. Pictet Asset Management Holding SA now owns 2,558,865 shares of the company's stock worth $48,439,000 after purchasing an additional 1,229,757 shares during the period. Hedge funds and other institutional investors own 92.92% of the company's stock.

Denali Therapeutics Stock Performance

Shares of DNLI stock opened at $20.39 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.37 and a quick ratio of 8.32. The firm has a 50-day moving average of $23.12 and a 200-day moving average of $21.89. Denali Therapeutics has a one year low of $13.28 and a one year high of $27.30. The company has a market cap of $3.26 billion, a P/E ratio of -7.18 and a beta of 1.01.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.17). The company had revenue of $3.60 million for the quarter, compared to analyst estimates of $2.15 million. During the same quarter in the previous year, the business posted ($0.72) EPS. Equities research analysts forecast that Denali Therapeutics will post -2.67 EPS for the current fiscal year.

About Denali Therapeutics

Denali Therapeutics Inc is a biotechnology company focused on discovering and developing medicines for patients with neurodegenerative diseases. The company is headquartered in South San Francisco, California, and was founded in 2013 by a team that included Chief Executive Officer Ryan Watts.

Denali's research is built around its blood-brain barrier transport technologies, which are designed to help therapeutic molecules reach the brain. The company applies these technologies to potential treatments for conditions including Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, lysosomal storage disorders and other neurodegenerative diseases.

Its pipeline has included investigational therapies directed at targets such as LRRK2, TREM2 and RIPK1, as well as enzyme-replacement approaches intended to improve delivery of treatments to the central nervous system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.